|
|||||
|
|
Melatonin,a toll-like receptor inhibitor: Current status and future perspectives |
|
| Authors: | Omid Reza Tamtaji Moein Mobini Russel J Reiter Abolfazl Azami Mohammad Saeed Gholami Zatollah Asemi |
| Institution: | 1. Halal Research Center of IRI, FDA, Tehran, Iran;2. Kinesiology Department, University of Calgary, Calgary, Alberta, Canada;3. Department of Cellular and Structural Biology, University of Texas Health Science Center, San Antonio, Texas;4. Anatomical Sciences Research Center, Kashan University of Medical Sciences, Kashan, Iran;5. Skull Base Research Center, Hazrat Rasoul Akram Hospital, Iran University of Medical Sciences, Tehran, Iran
Student Research Committee, School of Allied Medicine, Iran University of Medical Sciences, Tehran, Iran;6. Research Center for Biochemistry and Nutrition in Metabolic Diseases, Kashan University of Medical Sciences, Kashan, Iran |
| Abstract: | Toll-like receptors (TLRs) are crucial activators of inflammatory responses, they are considered immune receptors. TLRs are of fundamental importance in the pathophysiology of disorders related to inflammation including neurodegenerative diseases and cancer. Melatonin is a beneficial agent in the treatment of inflammatory and immune disorders. Melatonin is potent anti-inflammatory hormone that regulates various molecular pathways. Withal, limited studies have evaluated the inhibitory role of melatonin on TLRs. This review summarizes the current knowledge related to the effects of melatonin on TLRs in some common inflammatory and immunity disorders. |
| Keywords: | inflammation melatonin myeloid differentiation factor 88 toll-like receptor |